Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

IMS 2022 | IMS nursing highlights: talquetamab-induced toxicities, QoL tools & psychological impact of MRD

Monica Morris • 26 Aug 2022
IMS 2022
Multiple Myeloma Antibodies Talquetamab

Monica Morris, MSc, RN, Myeloma UK, Edinburgh, UK, shares some of the most exciting abstracts that were shared in one of the Nursing Symposia oral abstracts sessions, including managing oral and skin toxicities induced by talquetamab treatment, patients’ opinions on quality of life (QoL) tools, and the psychological impact of measurable residual disease (MRD) results on patients. This interview took place at the 19th International Myeloma Society Meeting (IMS) held in Los Angeles, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Monica Morris

3:16
Using feedback to improve the experience of patients with multiple myeloma in the UK
Monica Morris • 26 Aug 2022
3:09
Projects & goals of Myeloma UK
Monica Morris • 26 Aug 2022

Related Videos

1:47
Looking forward to the Miami Myeloma MRD Virtual Meeting 2024
Ola Landgren • 13 Apr 2024
2:27
The encouraging results of the LINKER-MM1 trial: safety and efficacy of linvoseltamab in R/R myeloma
Faith Davies • 9 Apr 2024
0:37
Upcoming studies investigating linvoseltamab in myeloma
Faith Davies • 9 Apr 2024
3:23
Molecular characteristics associated with increased risk of disease progression in SMM
Mark Bustoros • 27 Sep 2023
The content of VJHemOnc is intended for healthcare professionals